4//SEC Filing
Swayze Eric 4
Accession 0000874015-26-000026
CIK 0000874015other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 5:35 PM ET
Size
20.0 KB
Accession
0000874015-26-000026
Insider Transaction Report
Form 4
Swayze Eric
EVP Research
Transactions
- Exercise/Conversion
Common Stock
2026-01-02$60.89/sh+5,125$312,061→ 35,578 total - Sale
Common Stock
2026-01-02$78.57/sh−5,125$402,671→ 30,453 total - Exercise/Conversion
Common Stock
2026-01-02$60.89/sh+18,338$1,116,601→ 48,791 total - Sale
Common Stock
2026-01-02$79.27/sh−18,338$1,453,653→ 30,453 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-02−5,125→ 22,403 totalExercise: $60.89From: 2021-01-02Exp: 2027-01-01→ Common Stock (5,125 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2026-01-02−18,338→ 4,065 totalExercise: $60.89From: 2020-01-02Exp: 2027-01-01→ Common Stock (18,338 underlying) - Award
Non-Qualified Stock Option (right to buy)
2026-01-02+19,350→ 19,350 totalExercise: $79.67From: 2027-01-02Exp: 2036-01-01→ Common Stock (19,350 underlying) - Award
Non-Qualified Stock Option (right to buy)
2026-01-02+150→ 150 total(indirect: by Son)Exercise: $79.67From: 2027-01-02Exp: 2036-01-01→ Common Stock (150 underlying)
Holdings
- 256(indirect: by Son)
Common Stock
Footnotes (5)
- [F1]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- [F4]Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
- [F5]Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.
Documents
Issuer
IONIS PHARMACEUTICALS INC
CIK 0000874015
Entity typeother
Related Parties
1- filerCIK 0001791058
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 5:35 PM ET
- Size
- 20.0 KB